1.Organ donation after cardiac death donor lungs assessment standards and maintenance experience
Yongbo XUAN ; Yuchen PAN ; Yufei ZHAN ; Aiguo LUO ; Guiqing MO ; Zhongquan ZHU ; Yan ZUO
Chinese Journal of Organ Transplantation 2016;37(1):39-41
Objective To summarize the assessment standards of organ donation after cardiac death (DCD) donor lungs application and donor lung function maintenance experience.Method From Jan.2013 to June 2015,139 cases of DCD donors were subjected to rigorous assessment and effective donor lung function maintenance,and 11 donor lungs for lung transplantation were obtained.The donor lung cold ischemia time was (526.8-± 12.6) min (312 to 675 min).Double lung transplantation was performed on 9 cases,and 2 cases received single lung transplantation.Result Perioperatively,1 lung transplant recipient died of pulmonary infection.The survived 10 recipients had no rejection after operation,and obtained good quality of life during discharge to the final follow-up.Condusion The effect of donor lung transplantation using organ donation is satisfactory.The assessment standards and functional maintenance of donor lung are important factors to guarantee the success of lung transplantation.
2.Evaluation criteria and maintenance experience of cardiac death organ donor heart from Chinese first category
Yuchen PAN ; Yongbo XUAN ; Yufei ZHAN ; Guiqing MO ; Feng SHI ; Jie HAN ; Xu MENG
Chinese Journal of Organ Transplantation 2015;36(9):540-543
Objective To summarize the evaluation standard of cardiac death organ donation from Chinese first category donor heart application and experience of donor heart function maintenance.Method From Jan.2013 to Jan.2015,donor hearts for heart transplantation were obtained in 18 cases of Chinese first category cardiac death organ donors from 109 cases of organ donation donors through rigorous assessment and effective donor heart function maintenance.The diagnosis of brain death was based on the diagnosis of brain death criteria (adult) by the neurological department of internal medicine,department of neurosurgery,and intensive care unit with brain death qualification.Organ donation work followed the basic principles of voluntary,free,fair,equitable and technical access.Result Eighteen case of heart transplantations were all operated with double lumen venous anastornosis.The cold ischemia time was (125.5+ 18.7) min (61-60 min),and cardiopulmonary bypass time was (130.4+ 12.5) min (99-193 min).In 18 heart transplantations,16 cases survived,and 2 eases died of acute right heart failure.During the follow-u period,the quality of life in the survival recipients was satisfactory.Conclusion Using cardiac death organ donation from Chinese first category donor heart transplantation has achieved good results.The accurate assessment of donor hearts and effective donor heart function maintenance are the key factors to guarantee the success of heart transplantation.
3.Optimization Design of Emergency Quick Fixation Device Based on ANSYS Workbench.
Yufei JING ; Hong CHEN ; Xiaoqiang ZHANG ; Zhan ZHAO ; Xudong YU ; Wei WANG
Chinese Journal of Medical Instrumentation 2021;45(5):512-516
OBJECTIVE:
A rapid fixation device is developed to solve the problems of emergency fixation and transportation of patients with spinal injury.
METHODS:
Through the analysis of the function,3D modeling design, finite element analysis and optimization design based on ANSYS Workbench, tensile strength verification experiment, we produced the prototype, and tested it, conducted a simulated rescue experiment.
RESULTS:
The fixation device designed can meet the demand of spinal injury patients for safe rescue after accidents, and the quality of the rapid fixation device was lighten by about 30% without reducing the intensity.
CONCLUSIONS
The method based on optimal design can obviously improve the structure design, and has reference significance for other related rescue equipment design.
Equipment Design
;
Finite Element Analysis
;
Humans
;
Tensile Strength
4.Rapid Health Technology Assessment for Effectiveness ,Safety and Economics of Ginkgo biloba Extract in the Treatment of Alzheimer ’s Disease
Xiaolei REN ; Yi LIU ; Yiqiu ZHAN ; Chunyan ZHANG ; Lin HUANG ; Yufei FENG
China Pharmacy 2020;31(22):2786-2790
OBJECTIVE:To rapidly evaluate the effectiveness ,safety and economics of Ginkgo biloba extract(EGb)in the treatment of Alzheimer ’s disease (AD)patients,and to provide evidence-based reference for clinical drug selection and decision. METHODS:Retrieved from PubMed ,Embase,Cochrane Library ,Web of Science ,CNKI,CBM,Wanfang database ,health technology assessment (HTA)organization websites and database during the inception to Aug. 10,2020,HTA reports ,systematic reviews/Meta-analysis,and pharmacoeconomic studies of EGb versus placebo in the treatment of AD were collected. After literature screening and data extration ,HTA checklist ,AMSTAR-2 scale and CHEERS scale were used respectively to evaluate the literature quality of the included HTA report ,systematic review/Meta-analysis and pharmacoeconomics studies. The conclusion of the included studies were summarized by using qualitative description. RESULTS :A total of 9 literatures were included ,involving 8 systematic reviews and 1 economic studies. In terms of effectiveness ,there was no statistical significance in MMSE score of EGb group,ADAS-Cog score of 120 mg EGb group ,compared with placebo group (P>0.05). Dementia Quality of Life (DQoL)score of EGb group was significantly higher than that of placebo group. The scores of short cognitive aptitude tests ,neuropsychiatric inventory(NPI),NPI caregiver version score ,ADAS-Cog score of 160 mg EGb group and 240 mg EGb group were significantly lower than those of control group (P<0.05). ADL scores of patients were inconsistent ;ADL scores of EGb group were significantly lower than those o f placebo group (P<0.05),or there was no significant diff erence between 2 groups(P>0.05); . subgroup analysis by dose showed that there was no RDY2019-39) significant difference in ADL score between 120 mg EGb group and placebo group (P>0.05);ADL score of 240 mg E-mail:renxiaolei83@126.com EGb group were signicantly lower than that of placebo group (P<0.05). Subgroup analysis of clinical global impression 010-88325751。E-mail:lyi1267@126.com change (CGIC) score showed that there was no significant difference in CGIC score between EGb group and placebo group after receiving <200 mg EGb and 26 weeks of treatment (P> 0.05);CGIC score of EGb group was significantly higher than that of placebo group after receiving >200 mg EGb and 24 weeks of treatment (P<0.05). In terms of safety ,there was no statistical significance in the incidence of ADR or the incidence of severe ADR between EGb group and placebo group (P>0.05). Subgroup analysis by dose showed that the incidence of ADR in 240 mg EGb group was significantly higher than placebo group (P<0.05). Economically ,EGb treatment for AD is cost-effective ,which could indirectly save the nursing costs of AD patients. CONCLUSIONS :The efficacy of EGb in the treatment of AD is uncertain , and the safety and economy are good.